Sun Pharma rises on entering into agreements to acquire stakes in Agatsa Software, Remidio Innovative Solutions
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Sun Pharmaceutical Industries is currently trading at Rs. 986.05, up by 2.50 points or 0.25% from its previous closing of Rs. 983.55 on the BSE.
The scrip opened at Rs. 990.00 and has touched a high and low of Rs. 992.15 and Rs. 974.75 respectively. So far 13122 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1071.90 on 30-Jan-2023 and a 52 week low of Rs. 789.75 on 17-Jun-2022.
Last one week high and low of the scrip stood at Rs. 1017.85 and Rs. 974.75 respectively. The current market cap of the company is Rs. 236550.43 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.01% and 9.51% respectively.
Sun Pharmaceutical Industries has entered into agreements to acquire equity shares (up to 26.09%) of Agatsa Software, which is an early-stage digital diagnostic devices company and to acquire equity shares (27.39%) of Remidio Innovative Solutions, which provides innovative products enabling early detection of eye diseases.
The company has entered into agreements to acquire minority stake in Agatsa Software and Remidio Innovative Solutions which are non-material investments by the Company in the allied areas.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
